Endobronchial brachytherapy

Mariette L. Yu, Eric Edell

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Lung cancer continues to be the leading cause of cancer death in both men and women in the United States. At the time of diagnosis, only a small percentage of patients are surgical candidates. It is not uncommon for patients to present with symptoms of malignant obstruction, such as hemoptysis, cough, dyspnea, and/or obstructive pneumonitis. Therapeutic options for localized disease include neodymium, ytrium, aluminum, garnet (ND:YAG) laser resection, photodynamic therapy (PDT), external beam radiation therapy, cryotherapy, and brachytherapy. These treatments offer palliation in late-stage or recurrent disease and may have curative potential in early, roentgenographically occult disease. Endobronchial brachytherapy is designed to bring radiation doses directly to the tumor for localized treatment. This allows intense radiation to the intraluminal tumor, sparing the surrounding normal tissue. There are several modes of brachytherapy used in the treatment of lung cancer. The most widely used and investigated is endobronchial or intraluminal brachytherapy. Iridium 192 is the most commonly used radiation source. Dose rates vary between institutions and to date there is no consensus as to the optimal dose and frequency of fractionation for brachytherapy. Intraluminal brachytherapy has been shown to be effective in the management of recurrent or obstructing bronchogenic carcinoma. It has an acceptable complication rate when used in both low-dose and high-dose rates. Preliminary evidence suggests that it may be effective as a curative treatment for very superficial radiographically occult cancer.

Original languageEnglish (US)
Pages (from-to)555-561
Number of pages7
JournalSeminars in Respiratory and Critical Care Medicine
Volume18
Issue number6
DOIs
StatePublished - Jan 1 1997

Fingerprint

Brachytherapy
Radiation
Lung Neoplasms
Neoplasms
Dose Fractionation
Therapeutics
Neodymium
Iridium
Cryotherapy
Hemoptysis
Bronchogenic Carcinoma
Photochemotherapy
Aluminum
Cough
Dyspnea
Cause of Death
Pneumonia
Lasers
Radiotherapy

Keywords

  • Brachytherapy
  • Laser therapy
  • Lung cancer
  • Radiation therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Endobronchial brachytherapy. / Yu, Mariette L.; Edell, Eric.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 18, No. 6, 01.01.1997, p. 555-561.

Research output: Contribution to journalReview article

Yu, Mariette L. ; Edell, Eric. / Endobronchial brachytherapy. In: Seminars in Respiratory and Critical Care Medicine. 1997 ; Vol. 18, No. 6. pp. 555-561.
@article{b1576e336d5c4093a36dd223e34d9831,
title = "Endobronchial brachytherapy",
abstract = "Lung cancer continues to be the leading cause of cancer death in both men and women in the United States. At the time of diagnosis, only a small percentage of patients are surgical candidates. It is not uncommon for patients to present with symptoms of malignant obstruction, such as hemoptysis, cough, dyspnea, and/or obstructive pneumonitis. Therapeutic options for localized disease include neodymium, ytrium, aluminum, garnet (ND:YAG) laser resection, photodynamic therapy (PDT), external beam radiation therapy, cryotherapy, and brachytherapy. These treatments offer palliation in late-stage or recurrent disease and may have curative potential in early, roentgenographically occult disease. Endobronchial brachytherapy is designed to bring radiation doses directly to the tumor for localized treatment. This allows intense radiation to the intraluminal tumor, sparing the surrounding normal tissue. There are several modes of brachytherapy used in the treatment of lung cancer. The most widely used and investigated is endobronchial or intraluminal brachytherapy. Iridium 192 is the most commonly used radiation source. Dose rates vary between institutions and to date there is no consensus as to the optimal dose and frequency of fractionation for brachytherapy. Intraluminal brachytherapy has been shown to be effective in the management of recurrent or obstructing bronchogenic carcinoma. It has an acceptable complication rate when used in both low-dose and high-dose rates. Preliminary evidence suggests that it may be effective as a curative treatment for very superficial radiographically occult cancer.",
keywords = "Brachytherapy, Laser therapy, Lung cancer, Radiation therapy",
author = "Yu, {Mariette L.} and Eric Edell",
year = "1997",
month = "1",
day = "1",
doi = "10.1055/s-2007-1009371",
language = "English (US)",
volume = "18",
pages = "555--561",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "6",

}

TY - JOUR

T1 - Endobronchial brachytherapy

AU - Yu, Mariette L.

AU - Edell, Eric

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Lung cancer continues to be the leading cause of cancer death in both men and women in the United States. At the time of diagnosis, only a small percentage of patients are surgical candidates. It is not uncommon for patients to present with symptoms of malignant obstruction, such as hemoptysis, cough, dyspnea, and/or obstructive pneumonitis. Therapeutic options for localized disease include neodymium, ytrium, aluminum, garnet (ND:YAG) laser resection, photodynamic therapy (PDT), external beam radiation therapy, cryotherapy, and brachytherapy. These treatments offer palliation in late-stage or recurrent disease and may have curative potential in early, roentgenographically occult disease. Endobronchial brachytherapy is designed to bring radiation doses directly to the tumor for localized treatment. This allows intense radiation to the intraluminal tumor, sparing the surrounding normal tissue. There are several modes of brachytherapy used in the treatment of lung cancer. The most widely used and investigated is endobronchial or intraluminal brachytherapy. Iridium 192 is the most commonly used radiation source. Dose rates vary between institutions and to date there is no consensus as to the optimal dose and frequency of fractionation for brachytherapy. Intraluminal brachytherapy has been shown to be effective in the management of recurrent or obstructing bronchogenic carcinoma. It has an acceptable complication rate when used in both low-dose and high-dose rates. Preliminary evidence suggests that it may be effective as a curative treatment for very superficial radiographically occult cancer.

AB - Lung cancer continues to be the leading cause of cancer death in both men and women in the United States. At the time of diagnosis, only a small percentage of patients are surgical candidates. It is not uncommon for patients to present with symptoms of malignant obstruction, such as hemoptysis, cough, dyspnea, and/or obstructive pneumonitis. Therapeutic options for localized disease include neodymium, ytrium, aluminum, garnet (ND:YAG) laser resection, photodynamic therapy (PDT), external beam radiation therapy, cryotherapy, and brachytherapy. These treatments offer palliation in late-stage or recurrent disease and may have curative potential in early, roentgenographically occult disease. Endobronchial brachytherapy is designed to bring radiation doses directly to the tumor for localized treatment. This allows intense radiation to the intraluminal tumor, sparing the surrounding normal tissue. There are several modes of brachytherapy used in the treatment of lung cancer. The most widely used and investigated is endobronchial or intraluminal brachytherapy. Iridium 192 is the most commonly used radiation source. Dose rates vary between institutions and to date there is no consensus as to the optimal dose and frequency of fractionation for brachytherapy. Intraluminal brachytherapy has been shown to be effective in the management of recurrent or obstructing bronchogenic carcinoma. It has an acceptable complication rate when used in both low-dose and high-dose rates. Preliminary evidence suggests that it may be effective as a curative treatment for very superficial radiographically occult cancer.

KW - Brachytherapy

KW - Laser therapy

KW - Lung cancer

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0031440714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031440714&partnerID=8YFLogxK

U2 - 10.1055/s-2007-1009371

DO - 10.1055/s-2007-1009371

M3 - Review article

AN - SCOPUS:0031440714

VL - 18

SP - 555

EP - 561

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 6

ER -